AI assistant
Alkermes plc. — Director's Dealing 2024
Jun 4, 2024
31048_dirs_2024-06-04_ebe4ae25-26eb-411e-9bdd-b7a66aa63f4f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2024-05-31
Reporting Person: GAYNOR RICHARD (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $20.81 | J | 1236 | Acquired | 2029-12-04 | Ordinary Shares (1236) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $20.81 | J | 224 | Acquired | 2029-12-04 | Ordinary Shares (224) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $16.52 | J | 256 | Acquired | 2030-05-20 | Ordinary Shares (256) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $18.45 | J | 230 | Acquired | 2030-12-02 | Ordinary Shares (230) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $24.24 | J | 313 | Acquired | 2031-06-14 | Ordinary Shares (313) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $30.86 | J | 231 | Acquired | 2032-07-07 | Ordinary Shares (231) | Direct |
| 2023-11-17 | Non Qualified Stock Option (Right to Buy) | $30.72 | J | 254 | Acquired | 2033-06-29 | Ordinary Shares (254) | Direct |
| 2023-11-17 | Restricted Stock Unit Award | $ | J | 119 | Acquired | Ordinary Shares (119) | Direct | |
| 2024-05-31 | Restricted Stock Unit Award | $ | A | 8013 | Acquired | Ordinary Shares (8013) | Direct | |
| 2024-05-31 | Non Qualified Stock Option (Right to Buy) | $23.40 | A | 17492 | Acquired | 2034-05-31 | Ordinary Shares (17492) | Direct |
Footnotes
F1: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F2: These options are fully vested in accordance with their terms.
F3: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
F4: Each restricted stock unit represents a contingent right to receive one ordinary share.
F5: Shares subject to the restricted stock unit award vest in full on 6/29/2024.
F6: Shares subject to the restricted stock unit award vest in full on 5/31/2025.
F7: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.